Persistent Inspiratory Muscle Weakness After Prolonged Intubation: MIP at Day 12 Predicts Failure to Recover in the Acute-Care Stay
Posted inCritical Care news Respiratory

Persistent Inspiratory Muscle Weakness After Prolonged Intubation: MIP at Day 12 Predicts Failure to Recover in the Acute-Care Stay

In patients extubated after ≥7 days of mechanical ventilation, 43% had persistent inspiratory muscle weakness at hospital discharge. Maximal inspiratory pressure (MIP) measured 12 days after diagnosis strongly predicted persistent weakness and may guide early rehabilitation and resource allocation.
RSV prefusion F bivalent vaccine protects older adults similarly whether or not they have atherosclerotic cardiovascular disease
Posted inCardiology news Respiratory

RSV prefusion F bivalent vaccine protects older adults similarly whether or not they have atherosclerotic cardiovascular disease

In a prespecified secondary analysis of the DAN‑RSV randomized trial, the bivalent RSV prefusion F vaccine showed comparable effectiveness against RSV‑related respiratory hospitalizations in adults ≥60 years with and without pre‑existing atherosclerotic cardiovascular disease (ASCVD); no clear reduction in major adverse cardiovascular events was observed.
Cefiderocol Non‑Inferior to Standard Therapy for Hospital‑Acquired Gram‑Negative Bacteraemia: Insights from the GAME CHANGER Trial
Posted inCritical Care Infectious Diseases news

Cefiderocol Non‑Inferior to Standard Therapy for Hospital‑Acquired Gram‑Negative Bacteraemia: Insights from the GAME CHANGER Trial

The GAME CHANGER randomized trial found cefiderocol non‑inferior to standard‑of‑care antibiotics for 14‑day mortality in hospital‑acquired and healthcare‑associated Gram‑negative bloodstream infection; no superiority was seen, including in carbapenem‑resistant infections.
Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis
Posted innews OB/GYN & Women's Health Oncology

Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis

The VENUSCANCER secondary analysis of 275,792 records from 103 population-based registries reveals wide global variation in stage at diagnosis, concordance with guideline-recommended initial treatments, and time to treatment for breast, cervical, and ovarian cancers — with consistent shortfalls in early detection in LMICs and marked intercountry variability in care.
Percutaneous Strategy (TAVI + FFR-guided PCI) Outperforms SAVR + CABG at 1 Year in Patients ≥70 with Severe Aortic Stenosis and Complex Coronary Disease: Results of the TCW Randomised Trial
Posted inCardiology news

Percutaneous Strategy (TAVI + FFR-guided PCI) Outperforms SAVR + CABG at 1 Year in Patients ≥70 with Severe Aortic Stenosis and Complex Coronary Disease: Results of the TCW Randomised Trial

The TCW trial randomized 172 patients ≥70 years with severe aortic stenosis and complex coronary disease to FFR-guided PCI plus TAVI versus SAVR plus CABG. At 1 year the percutaneous strategy met non-inferiority and demonstrated superiority for a composite endpoint driven by lower mortality and life‑threatening bleeding.
Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes
Posted inHematology-Oncology news

Non‑conditioned Autologous Gene Therapy Reverses Bone Marrow Failure in Fanconi Anaemia‑A: FANCOLEN‑1 Phase 1/2 and Long‑Term Outcomes

The FANCOLEN‑1 trial shows that infusion of autologous FANCA‑corrected CD34+ cells without cytotoxic conditioning produced sustained engraftment and clinical improvement in a majority of treated patients with Fanconi anaemia‑A, with an acceptable short‑term safety profile and no genotoxicity detected during follow‑up.
Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma
Posted innews Oncology

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, though hematologic toxicity was substantial.
Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER
Posted inCardiology news

Transseptal TMVR with the SAPIEN M3 Lowers 1‑Year Mortality/HF Rehospitalisation in Patients Unsuitable for Surgery or TEER

A multicountry, single‑arm pivotal trial of the SAPIEN M3 transseptal transcatheter mitral valve replacement (TMVR) in patients deemed unsuitable for surgery or TEER demonstrated a 1‑year composite rate of death or heart‑failure rehospitalisation of 25.2%, significantly below the prespecified 45% performance goal, with few intraprocedural complications.